间充质干细胞与免疫调节关系及其在肝癌治疗中的意义和潜在价值

摘要/Abstract

摘要： 肝癌是临床上常见的一种恶性肿瘤,发病率、复发率和死亡率逐年升高。间充质干细胞(MSC)可在肿瘤微环境与多细胞联系,在肝癌进展中起着至关重要的作用。目前研究证实,MSC与免疫调节存在一定联系,且对于肝细胞癌(HCC)有潜在应用价值,与以往研究不同的是,在联合免疫靶向及多种现代化方式治疗方面中,有着可逆转耐药性、高效率、提高放射治疗潜力及安全性。在肝癌发展的肿瘤微环境中相互作用,免疫细胞调节促进肿瘤免疫逃逸、转移与复发,MSC通过细胞-细胞相互作用或产生可溶性因子介导,其在临床上具有指导意义。本文对免疫调节在肝癌中的作用,以及MSC与免疫调节的关系、MSC在肝癌治疗中的潜在价值及MSC的HCC疗法进行综述,并为肝癌的诊疗、药物研发拓展思路。

农耀斌, 黄鸿娜, 黄晶晶, 杨树栋, 董芷辛, 陈绮华, 周伟. 间充质干细胞与免疫调节关系及其在肝癌治疗中的意义和潜在价值[J]. 肝脏, 2025, 30(3): 398-402.

/ 推荐

参考文献

[1] Mass E, Ballesteros I, Farlik M, et al. Specification of tissue-resident macrophages during organogenesis[J]. Science,2016,353(6304):aaf4238.
[2] Hide T, Komohara Y, Miyasato Y, et al. Oligodendrocyte progenitor cells and macrophages/microglia produce glioma stem cell niches at the tumor border[J]. EBioMedicine,2018,30:94-104.
[3] Naik S, Larsen S B, Cowley C J,et al. Two to tango: dialog between immunity and stem cells in health and disease[J]. Cell, 2018,175(4):908-920.
[4] Sehgal A, Donaldson D S, Pridans C, et al. The role of CSF1R-dependent macrophages in control of the intestinal stem-cell niche[J]. Nat Commun,2018,9(1):1272.
[5] Huang Y K, Wang M, Sun Y, et al. Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry[J]. Nat Commun, 2019,10(1):3928.
[6] Cassetta L, Fragkogianni S, Sims A H, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets[J]. Cancer Cell, 2019,588-602.e10.
[7] Engblom C, Pfirschke C, Pittet M J. The role of myeloid cells in cancer therapies[J]. Nat Rev Cancer,2016,447-462.
[8] Barilla R M, Diskin B, Caso R C, et al. Specialized dendritic cells induce tumor-promoting IL-10⁺IL-17⁺ FoxP3neg regulatory CD4⁺ T cells in pancreatic carcinoma[J]. Nat Commun,2019,10(1):1424.
[9] Ning N, Pan Q, Zheng F, et al. Cancer stem cell vaccination confers significant antitumor immunity[J]. Cancer Res, 2012,72(7):1853-1864.
[10] Veglia F, Sanseviero E, Gabrilovich D I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity[J]. Nat Rev Immunol, 2021,21(8):485-498.
[11] Zhou S L, Yin D, Hu Z Q, et al. A positive feedback loop between cancer stem-like cells and tumor-associated neutrophils controls hepatocellular carcinoma progression[J]. Hepatology, 2019,70(4):1214-1230.
[12] Lanier L L. NK cell recognition[J]. Annu Rev Immunol, 2005,23:225-274.
[13] Swain M G. Hepatic NKT cells: friend or foe?[J]. Clin Sci (Lond), 2008,114(7):457-466.
[14] Cormier E G, Tsamis F, Kajumo F, et al. CD81 is an entry coreceptor for hepatitis C virus[J]. Proc Natl Acad Sci U S A, 2004,101(19):7270-7274.
[15] Beier C P, Kumar P, Meyer K, et al. The cancer stem cell subtype determines immune infiltration of glioblastoma[J]. Stem Cells Dev,2012,21(15):2753-2761.
[16] Bayik D,Lathia J D. Cancer stem cell-immune cell crosstalk in tumour progression[J] .Nat Rev Cancer, 2021, 21(8): 526-536.
[17] Carambia A, Freund B, Schwinge D, et al. Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice[J]. J Hepatol, 2015,62(6):1349-1356.
[18] Shi C, Jia T, Mendez-Ferrer S,et al . Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands[J]. Immunity, 2011,34(4):590-601.
[19] Akiyama K, Chen C, Wang D,et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis[J]. Cell Stem Cell, 2012,10(5):544-555.
[20] Zhang Y, Cai W, Huang Q,et al. Mesenchymal stem cells alleviate bacteria-induced liver injury in mice by inducing regulatory dendritic cells[J]. Hepatology, 2014,59(2):671-682.
[21] Tsuchida T, Friedman S L. Mechanisms of hepatic stellate cell activation[J]. Nat Rev Gastroenterol Hepatol, 2017,14(7):397-411.
[22] Li YH, Shen S, Shao T, et al. Mesenchymal stem cells attenuate liver fibrosis by targeting Ly6Chi/lo macrophages through activating the cytokine-paracrine and apoptotic pathways[J]. Cell Death Discov, 2021,7(1):239.
[23] Li S, Zheng X, Li H, et al. Mesenchymal stem cells ameliorate hepatic ischemia/reperfusion injury via inhibition of neutrophil recruitment[J]. J Immunol Res, 2018,2018:7283703.
[24] Qin C C, Liu Y N, Hu Y, et al. Macrophage inflammatory protein-2 as mediator of inflammation in acute liver injury[J]. World J Gastroenterol, 2017,23(17):3043-3052.
[25] Wang H, Zhang H, Huang B, et al. Mesenchymal stem cells reverse high-fat diet Induced non-alcoholic fatty liver disease through suppression of CD4⁺ T lymphocytes in mice[J]. Mol Med Rep,2018,17(3):3769-3774.
[26] Chen Q H, Wu F, Liu L, et al. Mesenchymal stem cells regulate the Th17/Treg cell balance partly through hepatocyte growth factor in vitro[J]. Stem Cell Res Ther, 2020,11(1):91.
[27] Milosavljevic N, Gazdic M, Simovic Markovic B, et al. Mesenchymal stem cells attenuate acute liver injury by altering ratio between interleukin 17 producing and regulatory natural killer T cells[J]. Liver Transpl, 2017,23(8):1040-1050.
[28] Chen J, Ji T, Wu D, et al. Human mesenchymal stem cells promote tumor growth via MAPK pathway and metastasis by epithelial mesenchymal transition and integrin α5 in hepatocellular carcinoma[J]. Cell Death Dis, 2019,10(6):425.
[29] Wang C, Hu J, Chen Z, et al. Reversibility of hAT-MSCs phenotypic and metabolic changes after exposure to and withdrawal from HCC-conditioned medium through regulation of the ROS/MAPK/HIF-1α signaling pathway[J]. Stem Cell Res Ther, 2020,11(1):506.
[30] Yan X, Zhang D, Wu W, et al. Mesenchymal stem cells promote hepatocarcinogenesis via lncRNA-MUF interaction with ANXA2 and miR-34a[J]. Cancer Res, 2017,77(23):6704-6716.
[31] Liu Y, Ren H, Zhou Y, et al. The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming[J]. J Exp Clin Cancer Res, 2019,38(1):228.
[32] Liu J, Shi Y, Han J, et al. Quantitative tracking tumor suppression efficiency of human umbilical cord-derived mesenchymal stem cells by bioluminescence imaging in mice hepatoma model[J]. Int J Stem Cells, 2020,13(1):104-115.
[33] Tang Y M, Bao W M, Yang J H, et al. Umbilical cord-derived mesenchymal stem cells inhibit growth and promote apoptosis of HepG2 cells[J]. Mol Med Rep,2016,14(3):2717-2724.
[34] Serhal R, Saliba N, Hilal G, et al. Effect of adipose-derived mesenchymal stem cells on hepatocellular carcinoma: in vitro inhibition of carcinogenesis[J]. World J Gastroenterol,2019,25(5):567-583.
[35] Liu Q W, Li J Y, Zhang X C, et al. Human amniotic mesenchymal stem cells inhibit hepatocellular carcinoma in tumour-bearing mice[J]. J Cell Mol Med, 2020,24(18):10525-10541.
[36] Ye F, Jiang J, Zong C,et al. Sirt1-overexpressing mesenchymal stem cells drive the anti-tumor effect through their pro-inflammatory capacity[J]. Mol Ther, 2020,28(3):874-888.
[37] Endaya B, Guan S P, Newman J P, et al.Human mesenchymal stem cells preferentially migrate toward highly oncogenic human hepatocellular carcinoma cells with activated EpCAM signaling[J]. Oncotarget, 2017,8(33):54629-54639.
[38] Hajighasemlou S, Nikbakht M, Pakzad S, et al. Sorafenib and mesenchymal stem cell therapy: a promising approach for treatment of HCC[J]. Evid Based Complement Alternat Med, 2020,2020:9602728.
[39] Li H, Yang C, Shi Y, et al. Exosomes derived from siRNA against GRP78 modified bone-marrow-derived mesenchymal stem cells suppress Sorafenib resistance in hepatocellular carcinoma[J]. J Nanobiotechnology, 2018,16(1):103.
[40] Seyhoun I, Hajighasemlou S, Ai J, et al. Novel combination of mesenchymal stem cell-conditioned medium with sorafenib have synergistic antitumor effect of hepatocellular carcinoma cells[J]. Asian Pac J Cancer Prev,2019,20(1):263-267.
[41] Lou G, Chen L, Xia C, et al. MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway[J]. J Exp Clin Cancer Res,2020,39(1):4.
[42] Wu L, Tang Q, Yin X, et al. The therapeutic potential of adipose tissue-derived mesenchymal stem cells to enhance radiotherapy effects on hepatocellular carcinoma[J]. Front Cell Dev Biol, 2019,7:267.
[43] Schug C, Kitzberger C, Sievert W, et al. Radiation-induced amplification of TGFB1-induced mesenchymal stem cell-mediated sodium iodide symporter (NIS) gene 131I therapy[J]. Clin Cancer Res,2019,25(19):5997-6008.
[44] Zhang J, Hou L, Wu X, et al. Inhibitory effect of genetically engineered mesenchymal stem cells with Apoptin on hepatoma cells in vitro and in vivo[J]. Mol Cell Biochem, 2016,416(1-2):193-203.
[45] Szoor A, Vaidya A, Velasquez M P, et al. T cell-activating mesenchymal stem cells as a biotherapeutic for HCC[J]. Mol Ther Oncolytics,2017,6:69-79.
[46] Cai C, Hou L, Zhang J, et al. The inhibitory effect of mesenchymal stem cells with rAd-NK4 on liver cancer[J]. Appl Biochem Biotechnol, 2017,183(1):444-459.
[47] 李梦,周云,禹亚彬,等.长链非编码RNA肝癌高表达转录本促进人骨髓间充质干细胞向肝样细胞的分化[J].中国组织工程研究, 2019, 23(29): 4656-4661.
[48] Yoon A R, Hong J, Li Y, et al. Mesenchymal stem cell-mediated delivery of an oncolytic adenovirus enhances antitumor efficacy in hepatocellular carcinoma[J]. Cancer Res, 2019,79(17):4503-4514.
[49] El-Magd M A, Mohamed Y, El-Shetry E S, et al. Melatonin maximizes the therapeutic potential of non-preconditioned MSCs in a DEN-induced rat model of HCC[J]. Biomed Pharmacother,2019,114:108732.